Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Medicine, Ibrutinib, Bruton's tyrosine kinase, Internal medicine, Mantle cell lymphoma, and Cancer research.
S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up